Literature DB >> 17981259

An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

Giulio G Muccioli1, Nephi Stella.   

Abstract

The endocannabinoids anandamide and 2-arachidonoylglycerol, as well as several anandamide-related N-acylethanolamines, belong to a family of lipid transmitter that regulate fundamental physiological processes, including neurotransmission and neuroinflammation. Their precise quantification in biological matrices can be achieved by gas chromatography-mass spectrometry (GC-MS), but this method typically requires multiple time-consuming purification steps such as solid-phase extraction followed by HPLC. Here we report a novel solid-phase extraction procedure allowing for single-step, and thus higher throughput, purification of endocannabinoids and N-acylethanolamines before GC-MS quantification. We determined the minimal amount of mouse brain tissue required to reliably detect endocannabinoids and N-acylethanolamines when using this approach and provide direct evidence for quantification accuracy by using radioactive and deuterated standards spiked into mouse brain samples. Using this method, we found that mouse brain contains much higher levels of anandamide (>1 nmol/g tissue) than previously reported, whereas levels of 2-arachidonoylglycerol and other N-acylethanolamines are well within the range of previous reports. In addition, we show that mouse brain amounts of endocannabinoids and N-acylethanolamines differ depending on animal gender as well as on whether the tissue was fixed or not. Our study shows that endocannabinoid and N-acylethanolamine levels quantified in mouse brain by GC-MS depend closely on tissue amount and preparation as well as on animal gender and that, depending on such parameters, anandamide levels could be underestimated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981259      PMCID: PMC2344129          DOI: 10.1016/j.ab.2007.09.030

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  42 in total

1.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.

Authors:  A Giuffrida; L H Parsons; T M Kerr; F Rodríguez de Fonseca; M Navarro; D Piomelli
Journal:  Nat Neurosci       Date:  1999-04       Impact factor: 24.884

2.  Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids.

Authors:  Marc Steffens; Andreas Schulze-Bonhage; Rainer Surges; Thomas J Feuerstein
Journal:  Neurosci Lett       Date:  2005-09-02       Impact factor: 3.046

3.  Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.

Authors:  F Berrendero; N Sepe; J A Ramos; V Di Marzo; J J Fernández-Ruiz
Journal:  Synapse       Date:  1999-09-01       Impact factor: 2.562

4.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

5.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

Authors:  Amy C Porter; John-Michael Sauer; Michael D Knierman; Gerald W Becker; Michael J Berna; Jingqi Bao; George G Nomikos; Petra Carter; Frank P Bymaster; Andrea Baker Leese; Christian C Felder
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue.

Authors:  K Kempe; F F Hsu; A Bohrer; J Turk
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

7.  The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity.

Authors:  Sachin Patel; Erica J Carrier; W-S Vanessa Ho; David J Rademacher; Sonya Cunningham; D Sudarshan Reddy; J R Falck; Benjamin F Cravatt; Cecilia J Hillard
Journal:  J Lipid Res       Date:  2004-12-01       Impact factor: 5.922

Review 8.  Cannabinoid signaling in glial cells.

Authors:  Nephi Stella
Journal:  Glia       Date:  2004-12       Impact factor: 7.452

9.  Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis.

Authors:  S Kondo; T Sugiura; T Kodaka; N Kudo; K Waku; A Tokumura
Journal:  Arch Biochem Biophys       Date:  1998-06-15       Impact factor: 4.013

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  20 in total

1.  Pitfalls in the sample preparation and analysis of N-acylethanolamines.

Authors:  Christian Skonberg; Andreas Artmann; Claus Cornett; Steen Honoré Hansen; Harald S Hansen
Journal:  J Lipid Res       Date:  2010-05-05       Impact factor: 5.922

Review 2.  Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls.

Authors:  Matthew W Buczynski; Loren H Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons.

Authors:  William R Marrs; Eric A Horne; Silvia Ortega-Gutierrez; Jose Antonio Cisneros; Cong Xu; Yi Hsing Lin; Giulio G Muccioli; Maria L Lopez-Rodriguez; Nephi Stella
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

4.  The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.

Authors:  Barbara Bosier; Giulio G Muccioli; Didier M Lambert
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  Anti-inflammatory ω-3 endocannabinoid epoxides.

Authors:  Daniel R McDougle; Josephine E Watson; Amr A Abdeen; Reheman Adili; Megan P Caputo; John E Krapf; Rodney W Johnson; Kristopher A Kilian; Michael Holinstat; Aditi Das
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-07       Impact factor: 11.205

6.  The endocannabinoid system links gut microbiota to adipogenesis.

Authors:  Giulio G Muccioli; Damien Naslain; Fredrik Bäckhed; Christopher S Reigstad; Didier M Lambert; Nathalie M Delzenne; Patrice D Cani
Journal:  Mol Syst Biol       Date:  2010-07       Impact factor: 11.429

Review 7.  Measuring endocannabinoid hydrolysis: refining our tools and understanding.

Authors:  William Marrs; Nephi Stella
Journal:  AAPS J       Date:  2009-05-08       Impact factor: 4.009

8.  Changes in N-acylethanolamine Pathway Related Metabolites in a Rat Model of Cerebral Ischemia/Reperfusion.

Authors:  Aruna Kilaru; Pamela Tamura; Puja Garg; Giorgis Isaac; David Baxter; R Scott Duncan; Ruth Welti; Peter Koulen; Kent D Chapman; Barney J Venables
Journal:  J Glycomics Lipidomics       Date:  2011

9.  Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.

Authors:  Mireille Alhouayek; Julien Masquelier; Patrice D Cani; Didier M Lambert; Giulio G Muccioli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

10.  Genetic manipulation of palmitoylethanolamide production and inactivation in Saccharomyces cerevisiae.

Authors:  Giulio G Muccioli; Angela Sia; Paul J Muchowski; Nephi Stella
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.